Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lungs to provide immediate and effective protection in animal models against all major classes of pathogens.

Phase I/2a clinical trials demonstrated that PUL-042 was well tolerated in healthy individuals and subjects with COPD. Two phase 2 studies have completed enrollment for the prevention and treatment of COVID-19 with funding from the Department of Defense, with data read outs in Q3/Q4 2021. Phase 2 studies are being planned to assess the effectiveness of PUL-042 in preventing respiratory complications and improving outcomes in immunocompromised cancer patients.